Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Intervalo de año de publicación
1.
Clin. transl. oncol. (Print) ; 26(1): 178-189, jan. 2024.
Artículo en Inglés | IBECS | ID: ibc-229156

RESUMEN

Purpose Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life. Methods Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life. Results We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods. Conclusion This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes (AU)


Asunto(s)
Humanos , Cuidados Paliativos al Final de la Vida , Neoplasias/tratamiento farmacológico , Antineoplásicos/administración & dosificación , Enfermo Terminal
2.
Clin Transl Oncol ; 26(1): 178-189, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37286888

RESUMEN

PURPOSE: Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life. METHODS: Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life. RESULTS: We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods. CONCLUSION: This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes.


Asunto(s)
Antineoplásicos , Neoplasias , Humanos , Antineoplásicos/uso terapéutico , Muerte , Neoplasias/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA